Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products. Phosphagenics' core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms. Phosphagenics' shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR - Level 1 program was established in the U.S. with The Bank of New York Mellon (PPGNY) for U.S. investors to trade in Phosphagenics' stock on the 'over-the-counter' market. In July 2007, this was upgraded to the International OTCQX, a new premium market tier in the U.S. for international exchange-listed companies, operated by Pink Sheets, LLC.

	Fax	03 9605 5999
	Principal Sector	Health & Pharm
	Principal Industry	Biotechnology
	Listed	1993/08/09
	Homepage	www.phosphagenics.com

Stock Exchange Stock Code   ASX:POH POH LSE PSG  PINK:PPGNY PPGNY ADR QUOTE PPGNY

Phosphagenics Ltd Announce Successful Transdermal Oxycodone Clinical Trial Results (DEC 17, 2007)